文献速递妇科

比较子宫肌瘤管理方案选择:以患者为中心的结果(COMPARE-UF)登记研究:依据与设计

The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design.
PubMed 文献 · Am J Obstet Gynecol · 2018-05-08

COMPARE-UF是一项由美国医疗保健研究与质量局与以患者为中心的结果研究所资助的前瞻性登记研究,旨在为症状性子宫肌瘤不同手术方式提供比较有效性数据。研究纳入接受子宫切除术、肌瘤剔除术、子宫内膜消融术、射频消融术、子宫动脉栓塞术、磁共振引导聚焦超声或孕激素释放宫内节育器放置术的女性,随访3年,初始纳入2031例,其中42%自认为黑人或非裔美国人,40%≤40岁,肌瘤剔除术占46%,子宫切除术占38%。

要点

  • COMPARE-UF为前瞻性登记研究,纳入接受子宫肌瘤手术的女性,随访3年。
  • 初始2031例中,42%为黑人或非裔美国人,40%≤40岁,16%<35岁。
  • 肌瘤剔除术占所有手术46%,其中腹腔镜或机器人肌瘤剔除术占所有手术19%;子宫切除术占38%。

核心结论

  • COMPARE-UF将生成不同子宫肌瘤手术方式比较有效性的证据,帮助患者和照护者做出符合个体短期和长期偏好的知情决策。
  • 鉴于接受不同子宫肌瘤治疗的女性存在人口学差异,通过临床试验评估该病的比较有效性仍将困难,因此该登记研究提供优化证据。

研究设计与样本

  • COMPARE-UF为前瞻性登记研究(Clinicaltrials.gov,NCT02260752),由美国医疗保健研究与质量局与以患者为中心的结果研究所资助。
  • 在美国9个临床中心招募接受子宫肌瘤手术的女性,随访3年,通过在线门户或传统电话进行年度随访评估。
  • 中央数据抽象中心提供影像、手术或操作记录及病理报告信息;子宫肌瘤女性和其他利益相关者参与从研究设计到结果传播的所有环节。

主要发现

  • 初始纳入2031例女性,42%自认为黑人或非裔美国人,40%≤40岁,16%<35岁。
  • 肌瘤剔除术占所有手术46%,其中腹腔镜或机器人肌瘤剔除术占所有手术19%;子宫切除术占38%。

关键数值与推荐

  • 初始纳入2031例女性;肌瘤剔除术占46%,子宫切除术占38%,腹腔镜或机器人肌瘤剔除术占所有手术19%。
  • 42%自认为黑人或非裔美国人;40%≤40岁;16%<35岁。

临床怎么用

  • COMPARE-UF结果将通过传统学术途径和包括多种社交媒体平台的创新方法直接传播给患者、提供者和其他利益相关者。
  • COMPARE-UF初步目标将针对患者利益相关者确定的优先事项,比较不同手术在持久症状缓解、复发可能性、医疗并发症、生活质量和性功能改善、绝经年龄及生育和妊娠结局方面的差异。

局限性

  • 鉴于接受不同子宫肌瘤治疗的女性存在人口学差异,通过临床试验评估该病的比较有效性仍将困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uterine fibroids are common in premenopausal women, yet comparative effectiveness research on uterine fibroid treatments is rare. OBJECTIVE: The purpose of this study was to design and establish a uterine fibroid registry based in the United States to provide comparative effectiveness data regarding uterine fibroid treatment. STUDY DESIGN: We report here the design and initial recruitment for the Comparing Options for Management: Patient-centered REsults for Uterine Fibroids (COMPARE-UF) registry (Clinicaltrials.gov, NCT02260752), funded by the Agency for Healthcare Research and Quality in collaboration with the Patient-Centered Outcomes Research Institute. COMPARE-UF was designed to help answer critical questions about treatment options for women with symptomatic uterine fibroids. Women who undergo a procedure for uterine fibroids (hysterectomy, myomectomy [abdominal, hysteroscopic, vaginal, and laparoscopic/robotic], endometrial ablation, radiofrequency fibroid ablation, uterine artery embolization, magnetic resonance-guided focused ultrasound, or progestin-releasing intrauterine device insertion) at 1 of the COMPARE-UF sites are invited to participate in a prospective registry with 3 years follow up for postprocedural outcomes. Enrolled participants provide annual follow-up evaluation through an online portal or through traditional phone contact. A central data abstraction center provides information obtained from imaging, operative or procedural notes, and pathology reports. Women with uterine fibroids and other stakeholders are a key part of the COMPARE-UF registry and participate at all points from study design to dissemination of results. RESULTS: We built a network of 9 clinical sites across the United States with expertise in the care of women with uterine fibroids to capture geographic, racial, ethnic, and procedural diversity. Of the initial 2031 women who were enrolled in COMPARE-UF, 42% are self-identified as black or African American, and 40% are ≤40 years old, with 16% of participants <35 years old. Women who undergo myomectomy comprise the largest treatment group at 46% of all procedures, with laparoscopic or robotic myomectomy comprising the largest subset of myomectomies at 19% of all procedures. Hysterectomy is the second most common treatment within the registry at 38%. CONCLUSION: In response to priorities that were identified by our patient stakeholders, the initial aims within COMPARE-UF will address how different procedures that are used to treat uterine fibroids compare in terms of long-lasting symptom relief, potential for recurrence, medical complications, improvement in quality of life and sexual function, age at menopause, and fertility and pregnancy outcomes. COMPARE-UF will generate evidence on the comparative effectiveness of different procedural options for uterine fibroids and help patients and their caregivers make informed decisions that best meet an individual patient's short- and long-term preferences. Building on this infrastructure, the COMPARE-UF team of investigators and stakeholders, including patients, collaborate to identify future priorities for expanding the registry, such as assessing the efficacy of medical therapies for uterine fibroids. COMPARE-UF results will be disseminated directly to patients, providers, and other stakeholders by traditional academic pathways and by innovative methods that include a variety of social media platforms. Given demographic differences among women who undergo different uterine fibroid treatments, the assessment of comparative effectiveness for this disease through clinical trials will remain difficult. Therefore, this registry provides optimized evidence to help patients and their providers better understand the pros and cons of different treatment options so that they can make more informed decisions.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Stewart EA, Lytle BL, Thomas L, et al. The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. Am J Obstet Gynecol. 2018. PMID: 29750955. doi:10.1016/j.ajog.2018.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。